Fredun Pharmaceuticals’ board has recommended a 2:1 bonus issue, granting two new equity shares for every one held. This decision aims to reward shareholders, reflecting management's confidence in the company’s sustained earnings growth, scalability, and long-term value creation strategy.
Site référencé: The Economic Times